Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-α and ameliorates hepatosteatosis in diabetic db/db mice

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Qiu, Longxin ^a,b   Lin, Jianhui ^b   Xu, Fangui ^b   Gao, Yuehong ^b   Zhang, Cuilin ^a   Liu, Ying ^a   Luo, Yu ^c   Yang, James Y ^a  

^a XIAMEN UNIVERSITY   (China)

^b LONGYAN UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SHORT HAIRPIN RNA; TRIACYLGLYCEROL; ZOPOLRESTAT; BENZOTHIAZOLE DERIVATIVE; ENZYME INHIBITOR; PHTHALAZINE DERIVATIVE; SMALL INTERFERING RNA;

ACO GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOA5 GENE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME INHIBITION; FATTY LIVER; GENE; GENE EXPRESSION; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; CHEMISTRY; DRUG ANTAGONISM; LIVER; METABOLISM; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY;

ALDEHYDE REDUCTASE; ANIMALS; BENZOTHIAZOLES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FATTY LIVER; HYPERGLYCEMIA; LIVER; MALE; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PHTHALAZINES; PPAR ALPHA; RNA, SMALL INTERFERING; TRIGLYCERIDES;

EID: 84855180612     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/789730     Document Type: Article

References (47)

1. Hers H. G., Aldose reductase Biochimica et Biophysica Acta 1960 37 1 120 126
2. Clements R. S., The polyol pathway. A historical review Drugs 1986 32 2 3 5
3. Brownlee M., Biochemistry and molecular cell biology of diabetic complications Nature 2001 414 6865 813 820 (Pubitemid 34000785)
4. Oates P. J., Mylari B. L., Aldose reductase inhibitors: therapeutic implications for diabetic complications Expert Opinion on Investigational Drugs 1999 8 12 2095 2119
5. Alexiou P., Pegklidou K., Chatzopoulou M., Nicolaou I., Demopoulos V. J., Aldose reductase enzyme and its implication to major health problems of the 21st century Current Medicinal Chemistry 2009 16 6 734 752
6. Markus H. B., Raducha M., Harris H., Tissue distribution of mammalian aldose reductase and related enzymes Biochemical Medicine 1983 29 1 31 45 (Pubitemid 13160612)
7. Clements R. S., Weaver J. P., Winegrad A. L., The distribution of polyol: NADP oxidoreductase in mammalian tissues Biochemical and Biophysical Research Communications 1969 37 2 347 353
8. Jeffery J., Jornvall H., Enzyme relationships in a sorbitol pathway that bypasses glycolysis and pentose phosphates in glucose metabolism Proceedings of the National Academy of Sciences of the United States of America 1983 80 4 I 901 905 (Pubitemid 13118062)
9. Roglans N., Vila L., Farre M., Impairment of hepatic Stat-3 activation and reduction of PPAR activity in fructose-fed rats Hepatology 2007 45 778 788 (Pubitemid 46450629)
10. Takahashi M., Hoshi A., Fujii J., Miyoshi E., Kasahara T., Suzuki K., Aozasa K., Taniguchi N., Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma Japanese Journal of Cancer Research 1996 87 4 337 341 (Pubitemid 26147846)
11. Takahashi M., Fujii J., Miyoshi E., Hoshi A., Taniguchi N., Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes International Journal of Cancer 1995 62 6 749 754
12. Lee K. W. Y., Ko B. C. B., Jiang Z., Cao D., Chung S. S. M., Overexpression of aldose reductase in liver cancers may contribute to drug resistance Anti-Cancer Drugs 2001 12 2 129 132 (Pubitemid 32207361)
13. Zeindl-Eberhart E., Haraida S., Liebmann S., Jungblut P. R., Lamer S., Mayer D., Jger G., Chung S., Rabes H. M., Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas Hepatology 2004 39 2 540 549 (Pubitemid 38228380)
14. Cusi K., Nonalcoholic fatty liver disease in type 2 diabetes mellitus Current Opinion in Endocrinology, Diabetes and Obesity 2009 16 2 141 149
15. Sanyal A. J., NASH: a global health problem Hepatology Research 2011 41 7 670 674
16. Xu J., Zhang J., Cai S., Dong J., Yang J. Y., Chen Z., Metabonomics studies of intact hepatic and renal cortical tissues from diabetic db/db mice using high-resolution magic-angle spinning 1H NMR spectroscopy Analytical and Bioanalytical Chemistry 2009 393 6-7 1657 1668
17. Qiu L., Wu X., Chau J. F. L., Szeto I. Y. Y., Wing Y. T., Guo Z., Chung S. K., Oates P. J., Chung S. S. M., Yang J. Y., Aldose reductase regulates hepatic peroxisome proliferator-activated receptor phosphorylation and activity to impact lipid homeostasis Journal of Biological Chemistry 2008 283 25 17175 17183
18. Yabe-Nishimura C., Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications Pharmacological Reviews 1998 50 1 21 33 (Pubitemid 28158840)
19. Kawasaki T., Akanuma H., Yamanouchi T., Increased fructose concentrations in blood and urine in patients with diabetes Diabetes Care 2002 25 2 353 357 (Pubitemid 41079635)
20. Yoshii H., Uchino H., Ohmura C., Watanabe K., Tanaka Y., Kawamori R., Clinical usefulness of measuring urinary polyol excretion by gas-chromatography/mass-spectrometry in type 2 diabetes to assess polyol pathway activity Diabetes Research and Clinical Practice 2001 51 2 115 123 (Pubitemid 32140863)
21. Kallai-Sanfacon M., Method of lowering lipid levels. US patent #4,492,706, 1985
22. Kawamura M., Eisenhofer G., Kopin I. J., Kador P. F., Lee Y. S., Fujisawa S., Sato S., Aldose reductase: an aldehyde scavenging enzyme in the intraneuronal metabolism of norepinephrine in human sympathetic ganglia Autonomic Neuroscience: Basic and Clinical 2002 96 2 131 139 (Pubitemid 34175165)
23. Peterson M. J., Method of lowering blood lipid levels. US patent #5,391,551, 1995
24. Abdelmegeed M. A., Yoo S. H., Henderson L. E., Gonzalez F. J., Woodcroft K. J., Song B. J., PPAR expression protects male mice from high fat-induced nonalcoholic fatty liver Journal of Nutrition 2011 141 4 603 610
25. Djouadi F., Weinheimer C. J., Saffitz J. E., Pitchford C., Bastin J., Gonzalez F. J., Kelly D. P., A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor -deficient mice Journal of Clinical Investigation 1998 102 6 1083 1091 (Pubitemid 28436268)
26. Duval C., Muller M., Kersten S., PPAR and dyslipidemia Biochimica et Biophysica Acta 2007 1771 961 971
27. Ip E., Farrell G. C., Robertson G., Hall P., Kirsch R., Leclercq I., Central role of PPAR -dependent hepatic lipid turnover in dietary steatohepatitis in mice Hepatology 2003 38 1 123 132 (Pubitemid 36775803)
28. Pyper S. R., Viswakarma N., Yu S., Reddy J. K., PPARalpha: energy combustion, hypolipidemia, inflammation and cancer Nuclear Receptor Signaling 2010 8 e002
29. Wu H. T., Chen C. T., Cheng K. C., Li Y. X., Yeh C. H., Cheng J. T., Pharmacological activation of peroxisome proliferator-activated receptor delta Improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice Hormone and Metabolic Research 2011 43 631 635
30. Vu-Dac N., Gervois P., Jakel H., Nowak M., Baugé E., Dehondt H., Staels B., Pennacchio L. A., Rubin E. M., Fruchart-Najib J., Fruchart J. C., Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor activators Journal of Biological Chemistry 2003 278 20 17982 17985 (Pubitemid 36799406)
31. Auwerx J., Schoonjans K., Fruchart J. C., Staels B., Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR Atherosclerosis 1996 124 S29 S37
32. Jrgens H., Haass W., Castaeda T. R., Schrmann A., Koebnick C., Dombrowski F., Otto B., Nawrocki A. R., Scherer P. E., Spranger J., Ristow M., Joost H. -G., Havel P. J., Tschp M. H., Consuming fructose-sweetened beverages increases body adiposity in mice Obesity Research 2005 13 7 1145 1156
33. Elliott S. S., Keim N. L., Stern J. S., Teff K., Havel P. J., Fructose, weight gain, and the insulin resistance syndrome American Journal of Clinical Nutrition 2002 76 5 911 922 (Pubitemid 35244659)
34. Samuel V. T., Fructose induced lipogenesis: from sugar to fat to insulin resistance Trends in Endocrinology and Metabolism 2011 22 2 60 65
35. Dekker M. J., Su Q., Baker C., Rutledge A. C., Adeli K., Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome American Journal of Physiology 2010 299 5 E685 E694
36. Anania F. A., Non-alcoholic fatty liver disease and fructose: bad for us, better for mice Journal of Hepatology 2011 55 1 218 220
37. Alisi A., Manco M., Pezzullo M., Nobili V., Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis Hepatology 2011 53 1 372 373
38. Lim J. S., Mietus-Snyder M., Valente A., Schwarz J. M., Lustig R. H., The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome Nature Reviews Gastroenterology and Hepatology 2010 7 5 251 264
39. Tetri L. H., Basaranoglu M., Brunt E. M., Yerian L. M., Neuschwander-Tetri B. A., Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent American Journal of Physiology 2008 295 5 G987 G995
40. Nagata R., Nishio Y., Sekine O., Nagai Y., Maeno Y., Ugi S., Maegawa H., Kashiwagi A., Single nucleotide polymorphism (-468 Gly to Ala) at the promoter region of sterol regulatory element-binding protein-1c associates with genetic defect of fructose-induced hepatic lipogenesis Journal of Biological Chemistry 2004 279 28 29031 29042 (Pubitemid 38915773)
41. Nagata R., Nishio Y., Sekine O., Nagai Y., Maeno Y., Ugi S., Maegawa H., Kashiwagi A., Erratum: Single nucleotide polymorphism (-468 Gly to Ala) at the promoter region of sterol regulatory element-binding protein-1c associates with genetic defect of fructose-induced hepatic lipogenesis (Journal of Biological Chemistry (2004) 279 (29031-29042)) Journal of Biological Chemistry 2004 279 35 37210 (Pubitemid 39129073)
42. Park J., Lemieux S., Lewis G. F., Kuksis A., Steiner G., Chronic exogenous insulin and chronic carbohydrate supplementation increase de novo VLDL triglyceride fatty acid production in rats Journal of Lipid Research 1997 38 12 2529 2536 (Pubitemid 28028137)
43. Roglans N., Bellido A., Rodrguez C., Cabrero., Novell F., Ros E., Zambn D., Laguna J. C., Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver Clinical Pharmacology and Therapeutics 2002 72 6 692 701 (Pubitemid 36021008)
44. Ackerman Z., Oron-Herman M., Grozovski M., Rosenthal T., Pappo O., Link G., Sela B. A., Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction Hypertension 2005 45 5 1012 1018 (Pubitemid 40628952)
45. Kanuri G., Spruss A., Wagnerberger S., Bischoff S. C., Bergheim I., Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells Laboratory Investigation 2011 91 6 885 895
46. Song M., Schuschke D. A., Zhou Z., High fructose feeding induces copper deficiency in sprague-dawley rats: a novel mechanism for obesity related fatty liver. Journal of Hepatology. In press
47. Abdelmalek M. F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R. J., Diehl A. M., Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease Hepatology 2010 51 6 1961 1971